Levobunolol

• CAT Number: I007649
• CAS Number: 47141-42-4
• Molecular Formula: C17H25NO3
• Molecular Weight: 291.391
• Purity: ≥95%
• Solubility: Soluble in DMSO, not in water
• Storage: 0 - 4°C for short term , or -20°C for long term.
• IUPAC Name: 5-[(2S)-3-(tert-butylamino)-2-hydroxypropoxy]-3,4-dihydro-2H-naphthalen-1-one
• InChI: InChI=1S/C17H25NO3/c1-17(2,3)18-10-12(19)11-21-16-9-5-6-13-14(16)7-4-8-15(13)20/h5-6,9,12,18-19H,4,7-8,10-11H2,1-3H3/t12-/m0/s1
• InChIKey: IXHBTMCLRNMKHZ-LBPRGKRZSA-N
• SMILES: CC(C)(C)NCC(COC1=CC=CC2=C1CCCC2=O)O

Levobunolol is a non-selective beta blocker. It is used topically to manage glaucoma.

Reference

1:Ocular Metabolism of Levobunolol: Historic and Emerging Metabolic Pathways. Argikar UA, Dumouchel JL, Dunne CE, Saran C, Cirello AL, Gunduz M.Drug Metab Dispos. 2016 Aug;44(8):1304-12. doi: 10.1124/dmd.116.070458. Epub 2016 May 17. PMID: 27190057 2:Allergic contact dermatitis caused by timolol with cross-sensitivity to levobunolol. Horcajada-Reales C, Rodríguez-Soria VJ, Suárez-Fernández R.Contact Dermatitis. 2015 Dec;73(6):368-9. doi: 10.1111/cod.12448. Epub 2015 Jul 31. No abstract available. PMID: 26227808 3:Bradyarrhythmias secondary to topical levobunolol hydrochloride solution. Lin L, Wang Y, Chen Y, Liu M.Clin Interv Aging. 2014 Oct 13;9:1741-5. doi: 10.2147/CIA.S69420. eCollection 2014. PMID: 25342892 Free PMC Article4:Effects of topical 0.5% levobunolol alone or in association with 2% dorzolamide compared with a fixed combination of 0.5% timolol and 2% dorzolamide on intraocular pressure and heart rate in dogs without glaucoma. Scardillo A, Pugliese M, De Majo M, Niutta PP, Pugliese A.Vet Ther. 2010 Fall;11(3):E1-6. PMID: 20960417 5:Comparison of effects of topical levobunolol to a combination of timolol-dorzolamide on intraocular pressure and pulse rate of healthy dogs. Pugliese M, Scardillo A, Niutta PP, Pugliese A.Vet Res Commun. 2009 Sep;33 Suppl 1:205-7. doi: 10.1007/s11259-009-9273-9. No abstract available. PMID: 19626454 6:Poly (epsilon-caprolactone) microparticles containing Levobunolol HCl prepared by a multiple emulsion (W/O/W) solvent evaporation technique: effects of some formulation parameters on microparticle characteristics. Karataş A, Sonakin O, Kiliçarslan M, Baykara T.J Microencapsul. 2009 Feb;26(1):63-74. doi: 10.1080/02652040802141039. PMID: 18608798 7:An in vivo confocal microscopy and impression cytology analysis of preserved and unpreserved levobunolol-induced conjunctival changes. Ciancaglini M, Carpineto P, Agnifili L, Nubile M, Fasanella V, Lanzini M, Calienno R, Mastropasqua L.Eur J Ophthalmol. 2008 May-Jun;18(3):400-7. PMID: 18465723 8:Vasodilatory mechanism of levobunolol on vascular smooth muscle cells. Dong Y, Ishikawa H, Wu Y, Yoshitomi T.Exp Eye Res. 2007 Jun;84(6):1039-46. Epub 2007 Jan 27. PMID: 17459374 9:Contact dermatitis to levobunolol eyedrops superimposed on IgE-mediated rhinoconjunctivitis. Blumetti B, Brodell RT, Helms SE, Brodell LP, Bredle DL.Ann Allergy Asthma Immunol. 2006 Dec;97(6):817-8. No abstract available. PMID: 17201244 10:Allergic contact dermatitis due to levobunolol with cross-sensitivity to befunolol. Nino M, Balato A, Ayala F, Balato N.Contact Dermatitis. 2007 Jan;56(1):53-4. No abstract available. PMID: 17177718